Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of CSTI-500 in Participants With Prader-Willi Syndrome

NCT07348601 is registered in ClinicalTrials.gov with ConSynance Therapeutics as lead sponsor.

NCT NCT07348601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of CSTI-500 in Participants With Prader-Willi Syndrome
Lead sponsor
ConSynance Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
May 31, 2026
Completion date
June 30, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prader-willi syndrome